Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus

Human Vaccines and Immunotherapeutics

Volumn 12, Issue 9, 2016, Pages 2351-2356

  Agrawal, Anurodh Shankar ^a   Tao, Xinrong ^a   Algaissi, Abdullah ^a,c   Garron, Tania ^a   Narayanan, Krishna ^a   Peng, Bi Hung ^b   Couch, Robert B ^b   Tseng, Chien Te K ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c JAZAN UNIVERSITY   (Saudi Arabia)

Author keywords

coronavirus; Eosinophils; immunopathology; Middle East Respiratory Syndrome; vaccination

Indexed keywords

ADJUVANT; GAMMA INTERFERON; INACTIVATED MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS VACCINE; INACTIVATED VIRUS VACCINE; INTERLEUKIN 13; INTERLEUKIN 5; MAJOR BASIC PROTEIN; MIFAMURTIDE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; INACTIVATED VACCINE; VIRUS ANTIBODY; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; AUTOIMMUNE LUNG DISEASE; CONTROLLED STUDY; CORONAVIRUS INFECTION; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; EOSINOPHIL COUNT; HISTOPATHOLOGY; INFECTIOUS DOSE; INFLAMMATORY INFILTRATE; MIDDLE EAST RESPIRATORY SYNDROME; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; VACCINATION; VIRUS LOAD; ANIMAL; BLOOD; CORONAVIRUS INFECTIONS; HYPERSENSITIVITY; IMMUNOLOGY; LUNG; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PATHOLOGY;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CORONAVIRUS INFECTIONS; HYPERSENSITIVITY; LUNG; MICE, TRANSGENIC; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; VACCINES, INACTIVATED; VIRAL VACCINES;

EID: 84987811156     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2016.1177688     Document Type: Article

References (22)

1. Severe acute respiratory syndrome (SARS). Status of the outbreak and lessons for the immediate future; unmasking a new disease. http://www.who.int/csr/media/sars_wha.pdf
2. Middle East respiratory syndrome coronavirus (MERS-CoV). Summary and risk assessment of the current situation in Korea and China – as of 3 June 2015. http://www.who.int/csr/disease/coronavirus_infections/risk-assessment-3june2015/en/
3. C.T.Tseng, E.Sbrana, N.Iwata-Yoshikawa, P.C.Newman, T.Garron, R.L.Atmar, C.J.Peters, R.B.Couch. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PloS One 2012; 7:e35421; PMID:22536382; http://dx.doi.org/10.1371/journal.pone.0035421
4. M.Bolles, D.Deming, K.Long, S.Agnihothram, A.Whitmore, M.Ferris, W.Funkhouser, L.Gralinski, A.Totura, M.Heise, R.S.Baric. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J Virol 2011; 85:12201-15; PMID:21937658; http://dx.doi.org/10.1128/JVI.06048-11
5. A.S.Agrawal, T.Garron, X.Tao, B.H.Peng, M.Wakamiya, T.S.Chan, R.B.Couch, C.T.Tseng. Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease. J Virol 2015; 89:3659-70; PMID:25589660; http://dx.doi.org/10.1128/JVI.03427-14
6. X.Tao, T.Garron, A.S.Agrawal, A.Algaissi, B.H.Peng, M.Wakamiya, T.S.Chan, L.Lu, L.Du, S.Jiang, R.B.Couch, C.T.Tseng. Characterization and demonstration of the value of a lethal mouse model of middle east respiratory syndrome coronavirus infection and disease. J Virol 2015; 90:57-67; PMID:26446606; http://dx.doi.org/10.1128/JVI.02009-15
7. C.Huang, C.J.Peters, S.Makino. Severe acute respiratory syndrome coronavirus accessory protein 6 is a virion-associated protein and is released from 6 protein-expressing cells. J Virol 2007; 81:5423-6; PMID:17344286; http://dx.doi.org/10.1128/JVI.02307-06
8. X.Tao, F.Mei, A.Agrawal, C.J.Peters, T.G.Ksiazek, X.Cheng, C.T.Tseng. Blocking of exchange proteins directly activated by cAMP leads to reduced replication of middle east respiratory syndrome coronavirus. J Virol 2014; 88:3902-10; PMID:24453361; http://dx.doi.org/10.1128/JVI.03001-13
9. C.Protheroe, S.A.Woodruff, G.de Petris, V.Mukkada, S.I.Ochkur, S.Janarthanan, J.C.Lewis, S.Pasha, T.Lunsford, L.Harris, et al. A novel histologic scoring system to evaluate mucosal biopsies from patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol 2009; 7:749-755 e711; PMID:19345285; http://dx.doi.org/10.1016/j.cgh.2009.03.022
10. R.M.Locksley. Asthma and allergic inflammation. Cell 2010; 140:777-83; PMID:20303868; http://dx.doi.org/10.1016/j.cell.2010.03.004
11. T.A.Wynn. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 2004; 4:583-94.
12. N.Zhang, R.Channappanavar, C.Ma, L.Wang, J.Tang, T.Garron, X.Tao, S.Tasneem, L.Lu, C.T.Tseng, et al. Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. Cell Mol Immunol 2015; 13:180-90; PMID:25640653; http://dx.doi.org/10.1038/cmi.2015.03
13. T.A.Wynn. Type 2 cytokines:mechanisms and therapeutic strategies. Nature reviews. Immunol 2015; 15:271-82.
14. Y.Honda-Okubo, D.Barnard, C.H.Ong, B.H.Peng, C.T.Tseng, N.Petrovsky. Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology. J Virol 2015; 89:2995-3007; PMID:25520500; http://dx.doi.org/10.1128/JVI.02980-14
15. N.Iwata-Yoshikawa, A.Uda, T.Suzuki, Y.Tsunetsugu-Yokota, Y.Sato, S.Morikawa, M.Tashiro, T.Sata, H.Hasegawa, N.Nagata. Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine. J Virol 2014; 88:8597-614; PMID:24850731; http://dx.doi.org/10.1128/JVI.00983-14
16. Y.W.Teng, B.S.Graham. Anti IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxicT lymphocyte activity in mice challenged with respiratory syncytial virus. J Clin Invest 1994; 94:1963.
17. T.R.Johnson, A.R.Parker, J.E.Johnson, B.S.Graham. IL13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge. J Immunol 2003; 170:2037-45; PMID:12574374; http://dx.doi.org/10.4049/jimmunol.170.4.2037
18. Y.T.Lee, E.J.Ko, H.S.Kwang, J.S.Lee, K.H.Kim, Y.M.Kwon, S.M.Kang. Respiratory syncytial virus-like nanoparticle vaccination induces long-term protection without pulmonary disease by modulating cytokines and T-cells partially through alveolar macrophages. Int J Nanomed 2015; 10:4491-505
19. A.Z.Kapikian, R.H.Mitchell, R.M.Chanock, R.A.Shvedoff, C.E.Stewart. An epidemiological study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969; 89:405-21; PMID:4305197.
20. H.W.Kim, J.G.Canchola, C.D.Brandt, G.Pyles, R.M.Chanock, K.Jensen, R.H.Parrott. Respiratorysyncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969; 89:422-34; PMID:4305198.
21. D.Deming, T.Sheahan, M.Heise, B.Yount, N.Davis, A.Sims, M.Suther, J.Harkema, A.Whitmore, R.Piclkes, et al. Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med 2006; 3:2359-75; http://dx.doi.org/10.1371/journal.pmed.0030525
22. F.Yasui, C.Kai, M.Kitabatake, S.Inoue, M.Yoneda, S.Yokochi, R.Kase, S.Sekiguchi, K.Morita, T.Hishima, et al. Prior immunization with severee acute respiraory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. J. Immunol 2008; 181:6337-48; PMID:18941225; http://dx.doi.org/10.4049/jimmunol.181.9.6337